New drug combo aims to knock out CMV faster in lung transplant patients
NCT ID NCT07235683
First seen Nov 19, 2025 · Last updated May 13, 2026 · Updated 29 times
Summary
This study tests whether adding a drug called letermovir to the usual antiviral treatment helps clear CMV infection faster in people who have received a lung transplant. About 40 participants with active CMV will receive either letermovir or a placebo alongside standard care. The main goal is to see if more patients achieve viral clearance by week 3.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANT RECIPIENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Health Network, Toronto General Hospital
RECRUITINGToronto, Ontario, M5G 2C4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.